DermaVir Nanomedicine: The Next Generation DNA Vaccine
Dr. Julianna Lisziewicz, Chief Executive Officer of the Genetic Immunity, will be presenting “DermaVir Nanomedicine: The Next Generation DNA Vaccine” at Phacilitate’s 8th annual European Vaccine Forum, to be held from June 22-24, 2009 Barcelona, Spain.
“I look forward to discussing the latest developments on our nanomedicine and dendritic cell targeting delivery system with conference attendees and to learn more about the progress of other companies active in the fields of immune therapy and vaccines. This event, just like the Bio International Convention in Atlanta, will give us many opportunities to look for partnerships and, or to reach for greater exposure of our immunotherapeutics technology,” commented Julianna Lisziewicz, CEO of the Company.
8th annual European Vaccine Forum will take place in Barcelona in June 2009. Phacilitate’s 8th annual European Vaccine Forum will run in parallel this year to a new conference — the Active Immunotherapeutics Forum. Dr. Lisziewicz will be attending both conferences.
About Genetic Immunity
Genetic Immunity is a US/Hungarian biopharmaceutical company establishing leadership in Nanomedicines for immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for treating disease or repairing damaged tissues. By leveraging its proprietary immune amplification platform technology, the Company aims to address new markets for infectious diseases, cancer and allergies through the discovery, development and commercialization of topically administered nanomedicines. These indications represent a significant unmet medical need and the potential for alternative treatment approaches.
More information:
Vaccine Market
Global Pandemic Influenza Preparedness Market Forecast 2010-2015
The Active Immunotherapeutics Forum, June 22-24 2009, Barcelona
